Simultaneous Evaluation of Membrane Permeability and UDP-Glucuronosyltransferase-Mediated Metabolism of Food-Derived Compounds Using Human Induced Pluripotent Stem Cell-Derived Small Intestinal Epithelial Cells.


Journal

Drug metabolism and disposition: the biological fate of chemicals
ISSN: 1521-009X
Titre abrégé: Drug Metab Dispos
Pays: United States
ID NLM: 9421550

Informations de publication

Date de publication:
01 2022
Historique:
received: 01 07 2021
accepted: 18 10 2021
pubmed: 22 10 2021
medline: 29 3 2022
entrez: 21 10 2021
Statut: ppublish

Résumé

Pharmacokinetic prediction after oral ingestion is important for quantitative risk assessment of food-derived compounds. To evaluate the utility of human intestinal absorption prediction, we compared the membrane permeability and metabolic activities of human induced pluripotent stem cell-derived small intestinal epithelial cells (hiPSC-SIECs) with Caco-2 cells or human primary enterocytes (hPECs). We found that membrane permeability in hiPSC-SIECs had better predictivity than that in Caco-2 cells against 21 drugs with known human intestinal availability (r = 0.830 and 0.401, respectively). Membrane permeability in hiPSC-SIECs was only 0.019-0.25-fold as compared with that in Caco-2 cells for 7 in 15 food-derived compounds, primarily those that were reported to undergo glucuronidation metabolism. The metabolic rates of the glucuronide conjugate were similar or higher in hiPSC-SIECs as compared with hPECs but lower in Caco-2 cells. Expression levels of UDP-glucuronosyltransferase (UGT) isoform mRNA in hiPSC-SIECs were similar or higher as compared with hPECs. Therefore, hiPSC-SIECs could be a useful tool for predicting human intestinal absorption to simultaneously evaluate membrane permeability and UGT-mediated metabolism. SIGNIFICANCE STATEMENT: Gastrointestinal absorption is an important step for predicting the internal exposure of food-derived compounds. This research revealed that human induced pluripotent stem cell-derived small intestinal cells (hiPSC-SIECs) had better predictivity of intestinal availability than Caco-2 cells; furthermore, the metabolic rates of UDP-glucuronosyltransferase (UGT) substrates of hiPSC-SIECs were closer to those of human primary enterocytes than those of Caco-2 cells. Therefore, hiPSC-SIECs could be a useful tool for predicting human intestinal absorption to simultaneously evaluate membrane permeability and UGT-mediated metabolism.

Identifiants

pubmed: 34670778
pii: dmd.121.000605
doi: 10.1124/dmd.121.000605
doi:

Substances chimiques

Glucuronides 0
Pharmaceutical Preparations 0
Glucuronosyltransferase EC 2.4.1.17

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

17-23

Informations de copyright

Copyright © 2021 by The American Society for Pharmacology and Experimental Therapeutics.

Auteurs

Takashi Kitaguchi (T)

Global Food Safety Institute, Nissin Foods Holdings Co., Ltd., Hachioji, Japan (T.K., T.M., M.I., K.O., K.K., M.T.); Department of Clinical Pharmacy, Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya, Japan (I.O., S.Q., T.I., T.M.); and Department of Health Pharmacy, Yokohama University of Pharmacy, Yokohama, Japan (N.H.) takashi.kitaguchi@nissin.com.

Taisei Mizota (T)

Global Food Safety Institute, Nissin Foods Holdings Co., Ltd., Hachioji, Japan (T.K., T.M., M.I., K.O., K.K., M.T.); Department of Clinical Pharmacy, Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya, Japan (I.O., S.Q., T.I., T.M.); and Department of Health Pharmacy, Yokohama University of Pharmacy, Yokohama, Japan (N.H.).

Mina Ito (M)

Global Food Safety Institute, Nissin Foods Holdings Co., Ltd., Hachioji, Japan (T.K., T.M., M.I., K.O., K.K., M.T.); Department of Clinical Pharmacy, Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya, Japan (I.O., S.Q., T.I., T.M.); and Department of Health Pharmacy, Yokohama University of Pharmacy, Yokohama, Japan (N.H.).

Katsutoshi Ohno (K)

Global Food Safety Institute, Nissin Foods Holdings Co., Ltd., Hachioji, Japan (T.K., T.M., M.I., K.O., K.K., M.T.); Department of Clinical Pharmacy, Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya, Japan (I.O., S.Q., T.I., T.M.); and Department of Health Pharmacy, Yokohama University of Pharmacy, Yokohama, Japan (N.H.).

Kazuhiro Kobayashi (K)

Global Food Safety Institute, Nissin Foods Holdings Co., Ltd., Hachioji, Japan (T.K., T.M., M.I., K.O., K.K., M.T.); Department of Clinical Pharmacy, Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya, Japan (I.O., S.Q., T.I., T.M.); and Department of Health Pharmacy, Yokohama University of Pharmacy, Yokohama, Japan (N.H.).

Isamu Ogawa (I)

Global Food Safety Institute, Nissin Foods Holdings Co., Ltd., Hachioji, Japan (T.K., T.M., M.I., K.O., K.K., M.T.); Department of Clinical Pharmacy, Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya, Japan (I.O., S.Q., T.I., T.M.); and Department of Health Pharmacy, Yokohama University of Pharmacy, Yokohama, Japan (N.H.).

Shimeng Qiu (S)

Global Food Safety Institute, Nissin Foods Holdings Co., Ltd., Hachioji, Japan (T.K., T.M., M.I., K.O., K.K., M.T.); Department of Clinical Pharmacy, Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya, Japan (I.O., S.Q., T.I., T.M.); and Department of Health Pharmacy, Yokohama University of Pharmacy, Yokohama, Japan (N.H.).

Takahiro Iwao (T)

Global Food Safety Institute, Nissin Foods Holdings Co., Ltd., Hachioji, Japan (T.K., T.M., M.I., K.O., K.K., M.T.); Department of Clinical Pharmacy, Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya, Japan (I.O., S.Q., T.I., T.M.); and Department of Health Pharmacy, Yokohama University of Pharmacy, Yokohama, Japan (N.H.).

Nobumitsu Hanioka (N)

Global Food Safety Institute, Nissin Foods Holdings Co., Ltd., Hachioji, Japan (T.K., T.M., M.I., K.O., K.K., M.T.); Department of Clinical Pharmacy, Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya, Japan (I.O., S.Q., T.I., T.M.); and Department of Health Pharmacy, Yokohama University of Pharmacy, Yokohama, Japan (N.H.).

Mitsuru Tanaka (M)

Global Food Safety Institute, Nissin Foods Holdings Co., Ltd., Hachioji, Japan (T.K., T.M., M.I., K.O., K.K., M.T.); Department of Clinical Pharmacy, Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya, Japan (I.O., S.Q., T.I., T.M.); and Department of Health Pharmacy, Yokohama University of Pharmacy, Yokohama, Japan (N.H.).

Tamihide Matsunaga (T)

Global Food Safety Institute, Nissin Foods Holdings Co., Ltd., Hachioji, Japan (T.K., T.M., M.I., K.O., K.K., M.T.); Department of Clinical Pharmacy, Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya, Japan (I.O., S.Q., T.I., T.M.); and Department of Health Pharmacy, Yokohama University of Pharmacy, Yokohama, Japan (N.H.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH